CymaBay is a biopharmaceutical company developing breakthrough therapies addressing unmet medical needs. Arhalofenate, the lead product candidate, possesses two therapeutic actions in a single drug: in gout patients it is intended to prevent painful attacks in joints while at the same time promoting excretion of uric acid by the kidney, thereby removing the root cause of this debilitating disease. Arhalofenate’s differentiated profile is intended for use in a large population, with significant advantages over marketed and emerging agents which have limitations in their efficacy, tolerability, and use in patients with common comorbidities. The Company is poised to follow arhalofenate with two additional clinical stage product candidates, one in diabetes and one in mixed dyslipidemia.
CymaBay Pipeline Overview
Our pipeline includes three clinical stage programs. Across this portfolio, a total of 23 clinical studies, including eleven Phase 2 studies, have been completed.